Hlib Chabaniuk

Summit Therapeutics stock falls 6.1% after Ivonescimab application update

Summit Therapeutics stock falls 6.1% after Ivonescimab application update
Summit Therapeutics stock falls 6.1% today

Summit Therapeutics issued an update on its Ivonescimab Biologics License Application. The stock is down 6.1% on the day at $14.15.

SMMT price prediction
24H 0.66%
$12.19
48H 0.33%
$12.15
7D -14.12%
$10.4
1M 9.66%
$13.28
3M 5.37%
$12.76
6M 13.79%
$13.78
12M 0.58%
$12.18
Current price: $12.11 -2.0250 14.33%
Real-time Data 13:03
Daily range 11.94 Arrow from to Icon 13.28
Weekly range 14.07 Arrow from to Icon 18.13
Loading...

Highlights

  • Summit Therapeutics announced that the FDA will decide on the Ivonescimab Biologics License Application on November 14, 2026.
  • Summit Therapeutics stock is down 6.1% on the day at $14.15.
  • 42 of 68 analysts rate Summit Therapeutics stock a buy, with a median price target of $32.81.

Summit Therapeutics provided an update on the regulatory status of its Ivonescimab Biologics License Application. The information appeared in a post from SMMT_TX, an account not affiliated with the company. The FDA is expected to decide on the application for Ivonescimab on November 14, 2026, according to Tech Times.

Limited further downside as bearish daily structure follows sharp drop

Stoch RSI is in oversold territory, suggesting downside is limited and conditions may favor stabilization. The chart shows a significant move lower with price remaining below its MA-20, MA-50, and MA-200, reinforcing the bearish daily structure. The nearest support is the weekly low at $14.06, with no clear sign of a reversal yet at this level.

Odds strongly favor further declines as traders watch key support

Traders should watch whether shares of Summit Therapeutics close above $15.76 or fall below $14.06 in the coming sessions. Right now, Stoch RSI remains in an oversold state, highlighting that further declines may be increasingly constrained. The recent move was sharp to the downside over the past week without a sustained trend; still, looking ahead over the next five trading days, the upside probability is less than 20% and the downside more than 80%, with an expected trading range of $12.32 to $15.97. A close above $15.76 would indicate buyers are returning, while a drop below $14.06 would confirm the move is being faded. On the weekly chart the longer-term picture stays firmly negative.

Earlier, analysts noted that Summit Therapeutics was under technical pressure despite a previously bullish trend structure. The recent regulatory update and further decline in share price underscore a firmly negative outlook, with traders advised to monitor the $14.06 support as a key downside risk in the days ahead.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.